Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 4/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4966804 | 1.00 | HDAC1 (0.52) | HDAC1OPRM1OPRD1OPRK1MEN1 | |
| SCHEMBL4965887 | 0.85 | OPRM1 (0.58) | HDAC1OPRM1OPRD1OPRK1RAB9A | |
| SCHEMBL5332629 | 0.85 | OPRM1 (0.58) | HDAC1OPRM1OPRD1OPRK1RAB9A | |
| SCHEMBL4963719 | 0.84 | MEN1 (0.45) | HDAC1MEN1KMT2AHRH3CHEK1 | |
| SCHEMBL4965823 | 0.84 | MEN1 (0.45) | HDAC1MEN1KMT2AHRH3CHEK1 | |
| SCHEMBL4968050 | 0.81 | OPRM1 (0.54) | HDAC1OPRM1OPRD1OPRK1CXCR4 | |
| Trifluoroacetic Acid SCHEMBL4964203 | 0.79 | OPRM1 (0.52) | HDAC1OPRM1OPRD1OPRK1RAB9A | |
| SCHEMBL5332624 | 0.78 | HRH3 (0.44) | OPRM1OPRD1OPRK1HRH3KDM4E | |
| SCHEMBL4965877 | 0.78 | HRH3 (0.44) | OPRM1OPRD1OPRK1HRH3KDM4E | |
| SCHEMBL4964153 | 0.76 | OPRM1 (0.56) | HDAC1OPRM1OPRD1OPRK1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1730140-B1 | OPIOID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2008-06-25 | — | — | EP | claimed |
| US-7288543-B2 | For therapy or prophylaxis of obesity and related diseases including eating disorders (bulimia, anorexia nervosa, etc.), diabetes, diabetic complications, diabetic retinopathy, sexual/reproductive disorders, depression, anxiety, epileptic seizure, hypertension, cerebral hemorrhage | ELI LILLY AND COMPANY (US) | 2007-10-30 | — | — | US | claimed |
| US-20070179129-A1 | Opioid receptor antagonists | ELI LILLY AND COMPANY | 2007-08-02 | — | — | US | claimed |
| EP-1730140-A1 | OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2006-12-13 | — | — | EP | claimed |
| WO-2005090337-A1 | OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-09-29 | — | — | WO | claimed |
| EP-1730140-B1 | OPIOID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2008-06-25 | — | — | EP | disclosed |
| US-7288543-B2 | For therapy or prophylaxis of obesity and related diseases including eating disorders (bulimia, anorexia nervosa, etc.), diabetes, diabetic complications, diabetic retinopathy, sexual/reproductive disorders, depression, anxiety, epileptic seizure, hypertension, cerebral hemorrhage | ELI LILLY AND COMPANY (US) | 2007-10-30 | — | — | US | disclosed |
| US-20070179129-A1 | Opioid receptor antagonists | ELI LILLY AND COMPANY | 2007-08-02 | — | — | US | disclosed |
| EP-1730140-A1 | OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005090337-A1 | OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179129-A1 | Opioid receptor antagonists | OPRK1, OPRM1, OPRL1 | HDAC1 703/4885OPRM1 2/4885OPRD1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.